Beam Therapeutics Inc’s filing revealed that its SVP, Finance and Treasurer Cavanagh Bethany J unloaded Company’s shares for reported $0.22 million on Feb 18 ’25. In the deal valued at $35.00 per share,6,287 shares were sold. As a result of this transaction, Cavanagh Bethany J now holds 37,527 shares worth roughly $0.92 million.
Then, Bellon Christine sold 10,000 shares, generating $340,000 in total proceeds. Upon selling the shares at $34.00, the Chief Legal Officer now owns 102,968 shares.
Before that, CHRISTINE BELLON bought 10,000 shares. Beam Therapeutics Inc shares valued at $340,000 were divested by the Officer at a price of $34.00 per share.
Scotiabank upgraded its Beam Therapeutics Inc [BEAM] rating to a Sector outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who increased its forecast for the stock in late January from “a Neutral” to “an Overweight”. Leerink Partners also remained covering BEAM and has increased its forecast on November 06, 2024 with a “an Outperform” recommendation from previously “Market perform” rating. Scotiabank started covering the stock on October 16, 2024. It rated BEAM as “a Sector outperform”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock jump 1.20% to $24.52. Over the last five days, the stock has lost -4.55%. Beam Therapeutics Inc shares have fallen nearly -1.13% since the year began. Nevertheless, the stocks have fallen -34.39% over the past one year. While a 52-week high of $36.75 was reached on 02/18/25, a 52-week low of $20.84 was recorded on 01/15/25. SMA at 50 days reached $26.93, while 200 days put it at $25.83.
Levels Of Support And Resistance For BEAM Stock
The 24-hour chart illustrates a support level at 23.48, which if violated will result in even more drops to 22.44. On the upside, there is a resistance level at 25.18. A further resistance level may holdings at 25.83. The Relative Strength Index (RSI) on the 14-day chart is 41.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.69, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.39%. Stochastics %K at 14.32% indicates the stock is a buying.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-02-28, dropping by 22065.0 shares to a total of 9.99 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 10.02 million shares. There was a decline of -0.22%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 23, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $80 price target.
